Melatonin marks circadian phase position and resets the endogenous circadian pacemaker in humans.

Alfred Lewy, Robert Sack, M. L. Blood, V. K. Bauer, N. L. Cutler, K. H. Thomas

Research output: Contribution to journalArticle

35 Citations (Scopus)

Abstract

Measuring the dim light melatonin onset (DLMO) is a useful and practical way to assess circadian phase position in humans. As a marker for the phase and period of the endogenous circadian pacemaker, the DLMO has been shown to advance with exposure to bright light in the morning and to delay with exposure to bright light in the evening. This 'phase response curve' (PRC) to light has been applied in the treatment of winter depression, jet lag and shift work, as well as circadian phase sleep disorders. Exogenous melatonin has phase-shifting effects described by a PRC that is about 12 h out of phase with the PRC to light. That is, melatonin administration in the morning causes phase delays and in the afternoon causes phase advances. All of the circadian phase disorders that have been successfully treated with appropriately timed exposure to bright light can be treated with appropriately scheduled melatonin administration. Melatonin administration is more convenient and therefore may be the preferred treatment.

Original languageEnglish (US)
Pages (from-to)303-317
Number of pages15
JournalCiba Foundation symposium
Volume183
StatePublished - 1995

Fingerprint

Melatonin
Light
Depression

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Lewy, A., Sack, R., Blood, M. L., Bauer, V. K., Cutler, N. L., & Thomas, K. H. (1995). Melatonin marks circadian phase position and resets the endogenous circadian pacemaker in humans. Ciba Foundation symposium, 183, 303-317.

Melatonin marks circadian phase position and resets the endogenous circadian pacemaker in humans. / Lewy, Alfred; Sack, Robert; Blood, M. L.; Bauer, V. K.; Cutler, N. L.; Thomas, K. H.

In: Ciba Foundation symposium, Vol. 183, 1995, p. 303-317.

Research output: Contribution to journalArticle

Lewy, A, Sack, R, Blood, ML, Bauer, VK, Cutler, NL & Thomas, KH 1995, 'Melatonin marks circadian phase position and resets the endogenous circadian pacemaker in humans.', Ciba Foundation symposium, vol. 183, pp. 303-317.
Lewy, Alfred ; Sack, Robert ; Blood, M. L. ; Bauer, V. K. ; Cutler, N. L. ; Thomas, K. H. / Melatonin marks circadian phase position and resets the endogenous circadian pacemaker in humans. In: Ciba Foundation symposium. 1995 ; Vol. 183. pp. 303-317.
@article{75f7de1a1670406088abe9420361f544,
title = "Melatonin marks circadian phase position and resets the endogenous circadian pacemaker in humans.",
abstract = "Measuring the dim light melatonin onset (DLMO) is a useful and practical way to assess circadian phase position in humans. As a marker for the phase and period of the endogenous circadian pacemaker, the DLMO has been shown to advance with exposure to bright light in the morning and to delay with exposure to bright light in the evening. This 'phase response curve' (PRC) to light has been applied in the treatment of winter depression, jet lag and shift work, as well as circadian phase sleep disorders. Exogenous melatonin has phase-shifting effects described by a PRC that is about 12 h out of phase with the PRC to light. That is, melatonin administration in the morning causes phase delays and in the afternoon causes phase advances. All of the circadian phase disorders that have been successfully treated with appropriately timed exposure to bright light can be treated with appropriately scheduled melatonin administration. Melatonin administration is more convenient and therefore may be the preferred treatment.",
author = "Alfred Lewy and Robert Sack and Blood, {M. L.} and Bauer, {V. K.} and Cutler, {N. L.} and Thomas, {K. H.}",
year = "1995",
language = "English (US)",
volume = "183",
pages = "303--317",
journal = "Ciba Foundation symposium",
issn = "0300-5208",
publisher = "Wiley Subscription Services",

}

TY - JOUR

T1 - Melatonin marks circadian phase position and resets the endogenous circadian pacemaker in humans.

AU - Lewy, Alfred

AU - Sack, Robert

AU - Blood, M. L.

AU - Bauer, V. K.

AU - Cutler, N. L.

AU - Thomas, K. H.

PY - 1995

Y1 - 1995

N2 - Measuring the dim light melatonin onset (DLMO) is a useful and practical way to assess circadian phase position in humans. As a marker for the phase and period of the endogenous circadian pacemaker, the DLMO has been shown to advance with exposure to bright light in the morning and to delay with exposure to bright light in the evening. This 'phase response curve' (PRC) to light has been applied in the treatment of winter depression, jet lag and shift work, as well as circadian phase sleep disorders. Exogenous melatonin has phase-shifting effects described by a PRC that is about 12 h out of phase with the PRC to light. That is, melatonin administration in the morning causes phase delays and in the afternoon causes phase advances. All of the circadian phase disorders that have been successfully treated with appropriately timed exposure to bright light can be treated with appropriately scheduled melatonin administration. Melatonin administration is more convenient and therefore may be the preferred treatment.

AB - Measuring the dim light melatonin onset (DLMO) is a useful and practical way to assess circadian phase position in humans. As a marker for the phase and period of the endogenous circadian pacemaker, the DLMO has been shown to advance with exposure to bright light in the morning and to delay with exposure to bright light in the evening. This 'phase response curve' (PRC) to light has been applied in the treatment of winter depression, jet lag and shift work, as well as circadian phase sleep disorders. Exogenous melatonin has phase-shifting effects described by a PRC that is about 12 h out of phase with the PRC to light. That is, melatonin administration in the morning causes phase delays and in the afternoon causes phase advances. All of the circadian phase disorders that have been successfully treated with appropriately timed exposure to bright light can be treated with appropriately scheduled melatonin administration. Melatonin administration is more convenient and therefore may be the preferred treatment.

UR - http://www.scopus.com/inward/record.url?scp=0029188702&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0029188702&partnerID=8YFLogxK

M3 - Article

C2 - 7656692

AN - SCOPUS:0029188702

VL - 183

SP - 303

EP - 317

JO - Ciba Foundation symposium

JF - Ciba Foundation symposium

SN - 0300-5208

ER -